Inactive Instrument

News Luye Pharma Group Ltd Singapore S.E.

Equities

LUYE

BMG5722Z1014

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Luye Pharma : Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI ...	06-28	PU
Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment	06-21	MT
Luye Pharma Group Ltd. Announces Its Jinyouping ® (Rotigotine Microspheres for Injection, Ly03003) Developed by the Group Has Been Approved	06-20	CI
Luye Pharma : Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China	06-19	PU
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets	06-12	MT
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China	06-11	CI
Luye Pharma : Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia	06-10	PU
Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch	06-06	MT
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	03-07	CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	03-04	MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	03-04	CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02-02	MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	02-01	CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	12-13	MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	12-13	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12-12	MT
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	12-12	PU
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12-12	CI
Luye Pharma Group Ltd. Announces Board Changes	12-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Luye Pharma Group Ltd Singapore S.E.

Equities

LUYE

BMG5722Z1014

Summary

Filters